Minerva Neurosciences, Inc (NASDAQ:NERV) Posts Earnings Results, Beats Estimates By $0.07 EPS
Minerva Neurosciences, Inc (NASDAQ:NERV) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.07, Bloomberg Earnings reports. During the same period in the prior year, the company earned ($0.18) EPS.
Shares of Minerva Neurosciences (NASDAQ NERV) traded up 3.12% during midday trading on Friday, reaching $6.60. The company’s stock had a trading volume of 130,007 shares. The company’s 50-day moving average price is $8.65 and its 200 day moving average price is $8.59. The company’s market capitalization is $242.25 million. Minerva Neurosciences has a 12-month low of $6.30 and a 12-month high of $14.92.
NERV has been the subject of a number of analyst reports. Zacks Investment Research upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 6th. ValuEngine upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. JMP Securities restated an “outperform” rating and set a $20.00 price objective (up from $17.00) on shares of Minerva Neurosciences in a research report on Thursday, June 1st. Finally, BidaskClub downgraded Minerva Neurosciences from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. Minerva Neurosciences has an average rating of “Hold” and an average price target of $16.67.
COPYRIGHT VIOLATION NOTICE: This article was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/minerva-neurosciences-inc-nasdaqnerv-posts-earnings-results-beats-estimates-by-0-07-eps.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.